The present disclosure relates to pharmaceutical formulations including abiraterone and a cyclic oligomer, as well as tablets including such pharmaceutical formulations, methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations or tablets.

The invention provides methods of preventing or treating hair loss by adoptive transfer of plasmacytoid dendritic cells and related compositions.

The invention provides methods of preventing or treating hair loss by adoptive transfer of plasmacytoid dendritic cells and related compositions.

A pharmaceutical composition for treating acute respiratory distress syndrome (ARDS), multiple end organ failure and survival in serious and life-threatening condition in patients with coronavirus disease 2019 (COVID-19) including (a) centhaquine; (b) antiviral therapies for SARS-CoV-2 infection (remdesivir, ivermectin, chloroquine, hydroxychloroquine, azythromicyn, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprevir, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), recombinant human angotensin-converting enzyme 2 (rhACE2), xiyanping, alpha-interferon, fludase (DAS181), eicosapentaenoic acid free fatty acid (EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, agonists of TLR2 TLR6, and TLR9), convalescent plasma, stem cells or their exosomes, immunomodulation and cytokine-targeted therapies (itolizumab, tocilizumab, sarilumab, acalabrutinib, piclidenoson, tradipitant, CD24Fc, emapalumab, anakinra, TJ003234, BLD-2660, blood purification systems, Spectra Optia Apheresis System, corticosteroids) oxygen concentrator and generator, T89, dantonic, plasminogen supplementation, plasminogen activators, alteplase; (c) budesonide, supportive therapies to reduce fever (like acetaminophen or ibuprofen), steroids (dexamethasone, prednisolone), anticoagulants (aspirin, heparin, non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anti-coagulant (DOAC), (d) inhaled synthetic surfactant, antibody to endotoxin, interferon-beta-1a, IV prostaglandin E1, neutrophil elastase inhibitors, nitric oxide and (e) an excipient. A method for preparing the composition for treating acute respiratory distress syndrome, multiple end organ failure and shock symptoms caused by coronaviruses infection, in particular SARS-CoV-2, MERS-CoV and SARS-CoV, using centhaquine and its analogues compound by mechanism of reduction of edema in the lungs, improvement in ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2 or SpO2/FiO2), blood oxygen saturation (SpO2), normalization in respiratory rate, reduction in lung infiltration, improvement in ARDS score, MODS, Ordinal Scale of COVID-19, and better blood flow and oxygenation of tissues.

A pharmaceutical composition for treating acute respiratory distress syndrome (ARDS), multiple end organ failure and survival in serious and life-threatening condition in patients with coronavirus disease 2019 (COVID-19) including (a) centhaquine; (b) antiviral therapies for SARS-CoV-2 infection (remdesivir, ivermectin, chloroquine, hydroxychloroquine, azythromicyn, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprevir, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), recombinant human angotensin-converting enzyme 2 (rhACE2), xiyanping, alpha-interferon, fludase (DAS181), eicosapentaenoic acid free fatty acid (EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, agonists of TLR2 TLR6, and TLR9), convalescent plasma, stem cells or their exosomes, immunomodulation and cytokine-targeted therapies (itolizumab, tocilizumab, sarilumab, acalabrutinib, piclidenoson, tradipitant, CD24Fc, emapalumab, anakinra, TJ003234, BLD-2660, blood purification systems, Spectra Optia Apheresis System, corticosteroids) oxygen concentrator and generator, T89, dantonic, plasminogen supplementation, plasminogen activators, alteplase; (c) budesonide, supportive therapies to reduce fever (like acetaminophen or ibuprofen), steroids (dexamethasone, prednisolone), anticoagulants (aspirin, heparin, non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anti-coagulant (DOAC), (d) inhaled synthetic surfactant, antibody to endotoxin, interferon-beta-1a, IV prostaglandin E1, neutrophil elastase inhibitors, nitric oxide and (e) an excipient. A method for preparing the composition for treating acute respiratory distress syndrome, multiple end organ failure and shock symptoms caused by coronaviruses infection, in particular SARS-CoV-2, MERS-CoV and SARS-CoV, using centhaquine and its analogues compound by mechanism of reduction of edema in the lungs, improvement in ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2 or SpO2/FiO2), blood oxygen saturation (SpO2), normalization in respiratory rate, reduction in lung infiltration, improvement in ARDS score, MODS, Ordinal Scale of COVID-19, and better blood flow and oxygenation of tissues.

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R.sup.1, R.sup.2, R.sup.5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia. ##STR00001##

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R.sup.1, R.sup.2, R.sup.5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia. ##STR00001##

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R.sup.1, R.sup.2, R.sup.5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia. ##STR00001##

The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound.

The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound.